Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.

CONCLUSION: Our study corroborates changes in the composition of circulating immune cells in response to fingolimod and delineates the respective implications at the RNA level. Our data may be valuable for comparing the effects of novel S1P receptor modulating agents, which may be a therapeutic option for patients with secondary progressive MS as well. PMID: 29314605 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29314605?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - January 3, 2018 Category: Neuroscience Authors: Angerer IC, Hecker M, Koczan D, Roch L, Friess J, Rüge A, Fitzner B, Boxberger N, Schröder I, Flechtner K, Thiesen HJ, Winkelmann A, Meister S, Zettl UK Tags: CNS Neurosci Ther Source Type: research